“Clinical Predictors of Response to Treatment with Tofacitinib (Janus Kinase Inhibitor) in Patients with Ankylosing Spondylitis”, IJBR, vol. 3, no. 4, pp. 175–181, Apr. 2025, doi: 10.70749/ijbr.v3i4.1020.